Intramuscular injections offer improved treatment adherence, ease in monitoring of adverse effects, and multiple administration sites.
Increasing the dose of fulvestrant from 250 mg to 500 mg improved median overall survival in women with locally advanced or metastatic estrogen receptor-positive breast cancer, according to updated data from the CONFIRM trial.
Studies show that alternate dosages of fulvestrant may be efficacious, and adverse effects are similar in all regimens.
Two FDA-approved drugs may be as effective in treating cervical cancer in human cells as they are in mice, say researchers at the University of Wisconsin-Madison School of Medicine and Public Health.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
- Single Chemotherapy Dose Informs Treatment Strategy for Advanced Laryngeal Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|